January 2016


Save-the-Date: ACT-AD Webinar on Personalized Medicine

On February 29 at 3:00 PM ET, ACT-AD will host a one-hour webinar on personalized medicine and Alzheimer’s disease. Speakers include:
  • Jason H. Karlawish, M.D., Professor of Medicine, Division of Geriatrics, Penn Medicine
  • J. Michael Ryan, M.D., Vice President, Neurodegeneration Therapeutic Area Head, Novartis Pharmaceuticals Corp.
  • Cara Tenenbaum, J.D., MBA, Senior Policy Advisor, Office of the Center Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration
  • Cynthia A. Bens, Executive Director, ACT-AD, Vice President, Public Policy, Alliance for Aging Research
 For more information, please contact Cynthia Bens. 

FDA Workshop to Gather Perspectives on Genetic Testing

On March 2, the U.S. Food and Drug Administration will hold an all-day workshop titled “Patient and Medical Professional Perspectives on the Return of Genetic Test Results” as part of the president’s Precision Medicine Initiative (PMI). The purpose of this public workshop is to understand patient and provider perspectives on receiving potentially medically relevant genetic test results. The topic(s) to be discussed will focus on better defining the specific information patients and providers prefer to receive, with an emphasis on the type(s) and amount of evidence available to interpret the results for medical purposes, how those results should be returned, and what information is needed to understand the results in the event that they could effectively aid in medical decision making. Case studies to guide the discussion are available here. You can register to attend and provide comments. Written comments to the docket are also encouraged by March 31, 2016.

ACT-AD a Media Partner for 10th Annual Drug Discovery Conference

ACT-AD is excited to be a media partner for the 10th Annual Drug Discovery for Neurodegeneration Conference to be held March 6-8 in Miami, Fla. Hosted by the Alzheimer’s Drug Discovery Foundation (ADDF), the conference “will educate scientists on the processes of translating basic research into novel therapies and will leave participants with a strong knowledge base and relevant resources to address the associated barriers and challenges in developing a drug.” It offers a comprehensive overview of the drug discovery process. For more information, please visit here.

How Will Alzheimer’s Disease Impact China?

Alzheimer’s disease isn’t just an American concern; it’s a burgeoning global issue. A report published in the journal eBioMedicine puts the focus on China. According to this article, occurrences of Alzheimer’s disease may quadruple by 2050, putting a massive strain on China’s economy. Some estimates put the annual price tag as high as $1 trillion by mid-century. The article’s authors make the case for investments in research. You can read it here. 

ACT-AD Welcomes New Member, APOE4.Info, Inc.

ACT-AD would like to welcome its newest member organization, APOE4.Info, Inc. This organization is dedicated to understanding the APOE4 gene and how it impacts health. It started out as an ordinary group of men and women, all united by one thing: They carry the APOE4 allele. Upon collaborating, they discovered that there was no consensus in the medical community for developing prevention strategies for those with this gene. This led to the formation of APOE4.Info, Inc.  For more information, please visit here.

Alzheimer’s Disease-Related Dementias 2016 Summit Set for March 29-30

Mark your calendars for March 29-30 as the National Institutes of Health holds its Alzheimer’s Disease-Related Dementias 2016 Summit on its campus in Bethesda, Md.  This summit features two days of focus on all things Alzheimer’s disease and its related dementias, including frontotemperal dementia (FTD), Lewy body, mixed, and vascular dementias. It’s an exciting time for Alzheimer’s research at NIH, and this conference is the place to be to find out the latest. ACT-AD is proud to be a sponsor. Get all the details here. 

Experts Say Urine Test Could Potentially Predict AD

According to researchers, a simple urine test may one day offer a prediction about the onset of AD. A study published in Scientific Reports finds mice that were given a chemical treatment that imitates the brain activity of a person with Alzheimer’s disease produced a urine odor that was different from that of mice without the chemical. Urine has been an unexplored potential biomarker source for Alzheimer’s disease. Go here to learn more.